Related Experiment Video
Updated: Jun 18, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Fosfluconazole for antifungal prophylaxis in very low birth weight infants
Daijiro Takahashi1, Tomohiko Nakamura, Reiko Shigematsu
1Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Abstract:
We conducted a retrospective case series study to evaluate the safety of fosfluconazole prophylaxis for preventing invasive fungal infection in VLBW infants with a central vascular access. Fosfluconazole was administered intravenously at a dose of 6 mg/kg everyday during which time a central venous catheter was placed. A total of 23 infants met the criteria for enrollment in our study. No cases of fungal infection were detected during the central venous catheter placement in the group. None of the infants had an elevated beta-D-glucan, and all of them were still alive at discharge. Regarding the liver and renal function, no statistically significant differences were observed before and at the end of fosfluconazole prophylaxis. The results of this study demonstrate that fosfluconazole prophylaxis in preventing invasive fungal infection was well tolerated by VLBW infants. This is a first report to describe antifungal prophylaxis using fosfluconazole for VLBW infants.
Insights
Fosfluconazole prophylaxis effectively prevented invasive fungal infections in very low birth weight infants. This antifungal treatment showed good tolerability, with no significant impact on liver or renal function.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Very low birth weight (VLBW) infants are highly susceptible to invasive fungal infections (IFIs).
- Central vascular catheters increase the risk of IFIs in this vulnerable population.
- Antifungal prophylaxis is crucial for IFI prevention in VLBW infants.
Purpose of the Study:
- To evaluate the safety and efficacy of fosfluconazole prophylaxis for preventing IFIs.
- To assess the tolerability of fosfluconazole in VLBW infants with central vascular access.
Main Methods:
- Retrospective case series study.
- Inclusion of 23 VLBW infants receiving intravenous fosfluconazole (6 mg/kg daily) during central venous catheter placement.
- Monitoring for fungal infections, beta-D-glucan levels, and liver/renal function.
Main Results:
- No cases of invasive fungal infection were detected during central venous catheter placement.
- No infants showed elevated beta-D-glucan levels.
- All infants survived until discharge.
- No statistically significant differences in liver and renal function were observed before and after prophylaxis.
Conclusions:
- Fosfluconazole prophylaxis is well-tolerated and effective in preventing IFIs in VLBW infants.
- This study represents the first report on fosfluconazole use for antifungal prophylaxis in VLBW infants.
More Related Videos
07:19A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
Published on: October 21, 2010
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Related Concept Videos
Antifungal Agents
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Cryptococcal Meningitis
Candidiasis
Fungal Phylum Microsporidia